These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Abnormalities of circulating lymphocyte subsets in haemophiliacs in an AIDS-free population. Carr R; Veitch SE; Edmond E; Peutherer JF; Prescott RJ; Steel CM; Ludlam CA Lancet; 1984 Jun; 1(8392):1431-4. PubMed ID: 6145879 [TBL] [Abstract][Full Text] [Related]
3. A study of cell mediated and humoral immunity in haemophilia and related disorders. Moffat EH; Bloom AL; Jones J; Matthews N; Newcombe RG Br J Haematol; 1985 Sep; 61(1):157-67. PubMed ID: 3931666 [TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up. Blombäck M; Kjellman H; Schulman S; Egberg N; Böttiger B; Wiechel B Infection; 1987; 15(4):248-52. PubMed ID: 3499399 [TBL] [Abstract][Full Text] [Related]
5. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate. Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573 [TBL] [Abstract][Full Text] [Related]
6. Immunologic aberrations, HIV seropositivity and seroconversion rates in patients with hemophilia B. Brettler DB; Brewster F; Levine PH; Forsberg A; Baker S; Sullivan JL Blood; 1987 Jul; 70(1):276-81. PubMed ID: 3109524 [TBL] [Abstract][Full Text] [Related]
7. [Immunological status of hemophiliacs: study of blood T-lymphocyte populations, serum immunoglobulins, and the prevalence of anti-LAV antibodies]. Aymard JP; Janot C; Briquel ME; André E; Schooneman F; Vigneron C; Legras B; Alexandre P; Streiff F Pathol Biol (Paris); 1985 Dec; 33(10):951-6. PubMed ID: 3005949 [TBL] [Abstract][Full Text] [Related]
8. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates. Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099 [TBL] [Abstract][Full Text] [Related]
9. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820 [TBL] [Abstract][Full Text] [Related]
10. Lymphocyte subset ratios and factor VIII usage in haemophilia. Beddall AC; Al-Rubei K; Williams MD; Hill FG Arch Dis Child; 1985 Jun; 60(6):530-6. PubMed ID: 3925894 [TBL] [Abstract][Full Text] [Related]
11. Immunological status and HIV antibodies in patients with haemophilia--a longitudinal study. Fuchs D; Hausen A; Reibnegger G; Werner ER; Vinazzer H; Dierich MP; Wachter H Wien Klin Wochenschr; 1988 Aug; 100(15):505-9. PubMed ID: 3140497 [TBL] [Abstract][Full Text] [Related]
12. Relationship of clinical and immunological abnormalities in haemophilia A to F VIII therapy and HIV exposure: a longitudinal study. Eagleton MC; Whelan CA; Sarsfield P; Carr B; Temperley IJ; Feighery C Eur J Haematol; 1988 Jan; 40(1):35-41. PubMed ID: 2963754 [TBL] [Abstract][Full Text] [Related]
13. Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort. Cuthbert RJ; Ludlam CA; Tucker J; Steel CM; Beatson D; Rebus S; Peutherer JF BMJ; 1990 Oct; 301(6758):956-61. PubMed ID: 1979015 [TBL] [Abstract][Full Text] [Related]
14. Inhibitors - cellular aspects and novel approaches for tolerance. Scott DW Haemophilia; 2014 May; 20 Suppl 4(0 4):80-6. PubMed ID: 24762281 [TBL] [Abstract][Full Text] [Related]
15. How to manage invasive procedures in children with haemophilia. Ljung RC; Knobe K Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160 [TBL] [Abstract][Full Text] [Related]
16. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group. Mannucci PM; Brettler DB; Aledort LM; Lusher JM; Abildgaard CF; Schwartz RS; Hurst D Blood; 1994 Apr; 83(7):1958-62. PubMed ID: 7908234 [TBL] [Abstract][Full Text] [Related]
17. Immunological abnormalities in haemophilia: are they caused by American factor VIII concentrate? Froebel KS; Madhok R; Forbes CD; Lennie SE; Lowe GD; Sturrock RD Br Med J (Clin Res Ed); 1983 Oct; 287(6399):1091-3. PubMed ID: 6226334 [TBL] [Abstract][Full Text] [Related]
18. HIV antibody status and immunological abnormalities in Polish haemophiliacs. Lopaciuk S; Kacperska E; Gloskowska-Moraczewska Z; Maslanka K; Uhrynowska M; Kraj M; Seyfried H Thromb Haemost; 1987 Feb; 57(1):41-3. PubMed ID: 3495899 [TBL] [Abstract][Full Text] [Related]
19. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates. Soria AG; Bouzas MB; Anselmo A; Ruibal-Ares BH Haematologica; 1991; 76(1):33-7. PubMed ID: 1829058 [TBL] [Abstract][Full Text] [Related]
20. Abnormal B-cell function in hemophiliacs treated with cryoprecipitate and factor VIII and IX concentrates. Gorski A; Gjerset GF; Martin PJ; Counts RB; Hansen JA Clin Immunol Immunopathol; 1986 Sep; 40(3):447-55. PubMed ID: 3089655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]